Is there a suitable way to purchase genuine Sotorasib?

Introduction: Sotorasib is a RAS GTPase family inhibitor developed by Amgen for the treatment of KRAS-mutated solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, Sotorasib received accelerated approval from the U.S. FDA for the treatment of adult patients with locally advanced or metastatic NSCLC with KRAS G12C mutations determined by an FDA-approved test and who have received at least one previous systemic therapy.

Is there a suitable way to purchase genuine Sotorasib

1. Hospital pharmacy: Patients can purchase directly in the hospital pharmacy. Since the drug is not currently available in mainland China, patients can purchase it in hospitals in Hong Kong or other regions. A doctor is required to issue a medical prescription before purchasing.

2. Pharmacies: Sotorasib is usually available in local pharmacies in countries or regions where it is listed, and a medical prescription is required before purchase.

3. Online pharmacies: Sotorasib can also be purchased in online pharmacies. Patients should choose a reputable online pharmacy to avoid buying counterfeit drugs.

4. Medical service institutions: Some domestic medical service institutions may provide purchasing services for Sotorasib. Patients can consult their customer service staff to find out whether they can purchase it.

When purchasing Sotorasib, patients need to ensure the authenticity and quality of the drug and follow the doctor's prescription and medication instructions. At the same time, patients should consult their doctor or other medical professional for advice on the use, dosage and possible side effects of the drug. In addition, patients should strictly follow the doctor's instructions when using sotoraxib, and promptly inform the doctor if side effects or poor efficacy occur.

Special population use of sotoracib

1. Pregnant women: There is currently no specific data on the use of sotoracib by pregnant women. In animal experiments, sotorasiib did not show adverse effects on embryonic development or embryonic lethality, even at high doses (4.6 times the clinical dose).

2. Breastfeeding women: There is no data on the presence of sotoracib or its metabolites in breast milk, its effects on breastfed children, or its effects on milk production. Due to the potential risk, female patients should avoid breastfeeding during treatment with sotoraxib and for 1 week after the last dose.

3. Use in children: The therapeutic effect of sotoracib in pediatric patients has not yet been determined.

Recommended dosage and usage of sotorasiib

is 960 mg, taken orally once a day, with or without food. Tablets should be swallowed whole and not chewed, crushed or split. If a dose is delayed by more than 6 hours, skip that dose and take the next dose as prescribed for the next day. Do not take both doses at the same time to make up for a missed dose.